Yoshihiro Ogawa

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Nao Fujimori · 12 shared papers, 2020–2026 · strength 2.15
   • Paper What is the best modality for diagnosing pancreatic cancer? DOI 10.1111/den.14283↗
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response hetero… DOI 10.1016/j.clnu.2026.106581↗
2. Masatoshi Murakami · 8 shared papers, 2020–2026 · strength 1.38
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
   • Paper Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship… DOI 10.21203/rs.3.rs-4088010/v1↗
3. Katsuhito Teramatsu · 7 shared papers, 2020–2026 · strength 1.16
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship… DOI 10.21203/rs.3.rs-4088010/v1↗
   • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
4. Kazuhide Matsumoto · 7 shared papers, 2020–2026 · strength 1.16
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship… DOI 10.21203/rs.3.rs-4088010/v1↗
   • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
5. Akihisa Ohno · 6 shared papers, 2021–2026 · strength 1.02
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship… DOI 10.21203/rs.3.rs-4088010/v1↗
   • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
6. Kohei Nakata · 4 shared papers, 2022–2025 · strength 0.67
   • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
   • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
   • Paper Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. DOI 10.1186/s12885-022-10207-0↗
7. Yoshinao Oda · 2 shared papers, 2024–2026 · strength 0.41
   • Paper Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. DOI 10.1038/s41388-025-03633-4↗
   • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
8. Masafumi Nakamura · 3 shared papers, 2021–2022 · strength 0.39
   • Paper Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. DOI 10.1186/s12885-022-10207-0↗
   • Paper Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic canc… DOI 10.1007/s12672-021-00462-1↗
   • Paper Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrin… DOI 10.1007/s12328-020-01234-0↗
9. Takehiro Takaoka · 2 shared papers, 2023–2024 · strength 0.37
   • Paper Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship… DOI 10.21203/rs.3.rs-4088010/v1↗
   • Paper Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable p… DOI 10.1111/ajco.13903↗
10. Kousei Ishigami · 2 shared papers, 2022–2025 · strength 0.36
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
    • Paper Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic canc… DOI 10.1007/s12672-021-00462-1↗
11. Toshiya Abe · 2 shared papers, 2022–2025 · strength 0.36
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
    • Paper Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic canc… DOI 10.1007/s12672-021-00462-1↗
12. Noboru Ideno · 2 shared papers, 2022–2025 · strength 0.36
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
    • Paper Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic canc… DOI 10.1007/s12672-021-00462-1↗
13. Naoki Ikenaga · 2 shared papers, 2022–2025 · strength 0.36
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
    • Paper Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic canc… DOI 10.1007/s12672-021-00462-1↗
14. Masami Miki · 2 shared papers, 2021–2022 · strength 0.26
    • Paper Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Ther… DOI 10.3390/jcm11175084↗
    • Paper Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrin… DOI 10.1007/s12328-020-01234-0↗
15. Ryosuke Matsukane · 1 shared paper, 2026 · strength 0.23
    • Paper Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response hetero… DOI 10.1016/j.clnu.2026.106581↗
16. Shigeru Ishida · 1 shared paper, 2026 · strength 0.23
    • Paper Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response hetero… DOI 10.1016/j.clnu.2026.106581↗
17. Mayako Uchida · 1 shared paper, 2026 · strength 0.23
    • Paper Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response hetero… DOI 10.1016/j.clnu.2026.106581↗
18. Nobuhiro Fujita · 1 shared paper, 2025 · strength 0.23
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
19. Yusuke Watanabe · 1 shared paper, 2025 · strength 0.23
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
20. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.23
    • Paper Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. DOI 10.1016/j.surg.2024.108958↗
21. Masafumi Nakamura · 1 shared paper, 2024 · strength 0.17
    • Paper Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. DOI 10.1007/s00535-024-02103-0↗
22. Tsukasa Miyagahara · 1 shared paper, 2023 · strength 0.15
    • Paper Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable p… DOI 10.1111/ajco.13903↗
23. Masayuki Furukawa · 1 shared paper, 2022 · strength 0.14
    • Paper Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Ther… DOI 10.3390/jcm11175084↗
24. Lingaku Lee · 1 shared paper, 2022 · strength 0.14
    • Paper Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Ther… DOI 10.3390/jcm11175084↗
25. Koki Oyama · 1 shared paper, 2022 · strength 0.14
    • Paper Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. DOI 10.1186/s12885-022-10207-0↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.